Cancer statistics, 2019.


Journal

CA: a cancer journal for clinicians
ISSN: 1542-4863
Titre abrégé: CA Cancer J Clin
Pays: United States
ID NLM: 0370647

Informations de publication

Date de publication:
01 2019
Historique:
received: 15 10 2018
accepted: 15 10 2018
pubmed: 9 1 2019
medline: 5 11 2019
entrez: 9 1 2019
Statut: ppublish

Résumé

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data, available through 2015, were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data, available through 2016, were collected by the National Center for Health Statistics. In 2019, 1,762,450 new cancer cases and 606,880 cancer deaths are projected to occur in the United States. Over the past decade of data, the cancer incidence rate (2006-2015) was stable in women and declined by approximately 2% per year in men, whereas the cancer death rate (2007-2016) declined annually by 1.4% and 1.8%, respectively. The overall cancer death rate dropped continuously from 1991 to 2016 by a total of 27%, translating into approximately 2,629,200 fewer cancer deaths than would have been expected if death rates had remained at their peak. Although the racial gap in cancer mortality is slowly narrowing, socioeconomic inequalities are widening, with the most notable gaps for the most preventable cancers. For example, compared with the most affluent counties, mortality rates in the poorest counties were 2-fold higher for cervical cancer and 40% higher for male lung and liver cancers during 2012-2016. Some states are home to both the wealthiest and the poorest counties, suggesting the opportunity for more equitable dissemination of effective cancer prevention, early detection, and treatment strategies. A broader application of existing cancer control knowledge with an emphasis on disadvantaged groups would undoubtedly accelerate progress against cancer.

Identifiants

pubmed: 30620402
doi: 10.3322/caac.21551
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

7-34

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2019 American Cancer Society.

Auteurs

Rebecca L Siegel (RL)

Scientific Director, Surveillance Research, American Cancer Society, Atlanta, GA.

Kimberly D Miller (KD)

Senior Associate Scientist, Surveillance Research, American Cancer Society, Atlanta, GA.

Ahmedin Jemal (A)

Scientific Vice President, Surveillance and Health Services Research, American Cancer Society, Atlanta, GA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH